1. Home
  2. |Insights
  3. |Crowell & Moring Represents Third Rock Ventures in $108 Million Series C Financing for Terremoto Biosciences

Crowell & Moring Represents Third Rock Ventures in $108 Million Series C Financing for Terremoto Biosciences

Firm News | less than 1 min read | 04.15.26

Boston and San Francisco – April 15, 2026: Crowell & Moring represented investor Third Rock Ventures in the closing of a $108 million Series C financing round for Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines.  

Along with Third Rock, the financing included support from existing investors OrbiMed, Novo Holdings, and Cormorant Asset Management, LP, as well as from new investors RA Capital Management, Deep Track Capital, Osage University Partners (OUP), and BeOne Medicines. Proceeds from the financing will enable Terremoto to advance its selective AKT1 inhibitor programs through Phase 1 clinical development for patients with cancer and rare diseases such as hereditary hemorrhagic telangiectasia. 

The financing transaction was led by partner Kurt Machemer (Boston). 


Insights

Firm News | 2 min read | 05.22.26

Crowell & Moring Represents Kanders & Company in Acquisition of Ginkgo Bioworks’ Biosecurity Business

May 22, 2026: A Crowell & Moring team represented Kanders & Company in a complex carveout transaction in which Kanders acquired the biosecurity business of publicly traded Ginkgo Bioworks. The resulting company, Perimeter Systems, has launched as the world’s first integrated biosecurity infrastructure platform, designed to transform biological signals into real-time intelligence and accelerate decisive response. At closing, Perimeter secured $60 million in growth capital, led by Kanders in partnership with SCS Financial, Goldcrest Capital, Four Cities Capital, and the Safe Artificial Intelligence Fund (SAIF)....

View All Insights